Therefore, those results suggested that SIRT4 may have a tumor-inhibitory role in pericarcinomatous tissues of HCC by inhibiting the development and migration of tumor cells and, thus, improving the prognosis of patients. Here, SIRT4 is linked to hepatocellular carcinoma.